Funcis A, Ravera B, Zinzi P, Solito M, Petracca M, Calabresi P
Eur J Neurol. 2024; 31(12):e16442.
PMID: 39444167
PMC: 11554869.
DOI: 10.1111/ene.16442.
DEgidio F, Castelli V, Cimini A, dAngelo M
Antioxidants (Basel). 2023; 12(3).
PMID: 36978821
PMC: 10045781.
DOI: 10.3390/antiox12030571.
Shi Y, Liu W, Yang Y, Ci Y, Shi L
Int J Mol Sci. 2023; 24(5).
PMID: 36902271
PMC: 10002862.
DOI: 10.3390/ijms24054839.
Song Y, Yoon J, Lee S
Exp Mol Med. 2021; 53(3):328-338.
PMID: 33742131
PMC: 8080805.
DOI: 10.1038/s12276-021-00580-4.
Salado-Manzano C, Perpina U, Straccia M, Molina-Ruiz F, Cozzi E, Rosser A
Front Cell Neurosci. 2020; 14:250.
PMID: 32848630
PMC: 7433375.
DOI: 10.3389/fncel.2020.00250.
No symphony without bassoon and piccolo: changes in synaptic active zone proteins in Huntington's disease.
Huang T, Smith R, Bacos K, Song D, Faull R, Waldvogel H
Acta Neuropathol Commun. 2020; 8(1):77.
PMID: 32493491
PMC: 7268643.
DOI: 10.1186/s40478-020-00949-y.
Glutamatergic fast-spiking parvalbumin neurons in the lateral hypothalamus: Electrophysiological properties to behavior.
Siemian J, Sarsfield S, Aponte Y
Physiol Behav. 2020; 221:112912.
PMID: 32289319
PMC: 8801204.
DOI: 10.1016/j.physbeh.2020.112912.
The Role of Hypothalamic Pathology for Non-Motor Features of Huntington's Disease.
Cheong R, Gabery S, Petersen A
J Huntingtons Dis. 2019; 8(4):375-391.
PMID: 31594240
PMC: 6839491.
DOI: 10.3233/JHD-190372.
Glycation in Huntington's Disease: A Possible Modifier and Target for Intervention.
Bras I, Konig A, Outeiro T
J Huntingtons Dis. 2019; 8(3):245-256.
PMID: 31322580
PMC: 6839463.
DOI: 10.3233/JHD-190366.
Protective Effects of Antioxidants in Huntington's Disease: an Extensive Review.
Essa M, Moghadas M, Ba-Omar T, Qoronfleh M, Guillemin G, Manivasagam T
Neurotox Res. 2019; 35(3):739-774.
PMID: 30632085
DOI: 10.1007/s12640-018-9989-9.
A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.
Silajdzic E, Bjorkqvist M
J Huntingtons Dis. 2018; 7(2):109-135.
PMID: 29614689
PMC: 6004896.
DOI: 10.3233/JHD-170273.
Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism.
Vercruysse P, Vieau D, Blum D, Petersen A, Dupuis L
Front Mol Neurosci. 2018; 11:2.
PMID: 29403354
PMC: 5780436.
DOI: 10.3389/fnmol.2018.00002.
Neural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challenges.
Kerkis I, Haddad M, Valverde C, Glosman S
Stem Cell Res Ther. 2015; 6:232.
PMID: 26667114
PMC: 4678723.
DOI: 10.1186/s13287-015-0248-1.
A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington's Disease.
Kalliolia E, Silajdzic E, Nambron R, Costelloe S, Martin N, Hill N
PLoS One. 2015; 10(10):e0138848.
PMID: 26431314
PMC: 4592185.
DOI: 10.1371/journal.pone.0138848.
Functional Differences Between Direct and Indirect Striatal Output Pathways in Huntington's Disease.
Galvan L, Andre V, Wang E, Cepeda C, Levine M
J Huntingtons Dis. 2014; 1(1):17-25.
PMID: 25063187
PMC: 4116084.
DOI: 10.3233/JHD-2012-120009.
Huntingtin-associated protein 1 regulates exocytosis, vesicle docking, readily releasable pool size and fusion pore stability in mouse chromaffin cells.
Mackenzie K, Duffield M, Peiris H, Phillips L, Zanin M, Teo E
J Physiol. 2013; 592(7):1505-18.
PMID: 24366265
PMC: 3979608.
DOI: 10.1113/jphysiol.2013.268342.
Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility.
Chen J, Wang E, Cepeda C, Levine M
Front Neurosci. 2013; 7:114.
PMID: 23847463
PMC: 3701870.
DOI: 10.3389/fnins.2013.00114.
Sleep and circadian dysfunction in neurodegenerative disorders: insights from a mouse model of Huntington's disease.
Kuljis D, Schroeder A, Kudo T, Loh D, Willison D, Colwell C
Minerva Pneumol. 2013; 51(3):93-106.
PMID: 23687390
PMC: 3655901.
Changes in the striatal proteome of YAC128Q mice exhibit gene-environment interactions between mutant huntingtin and manganese.
Wegrzynowicz M, Holt H, Friedman D, Bowman A
J Proteome Res. 2011; 11(2):1118-32.
PMID: 22191580
PMC: 3319668.
DOI: 10.1021/pr200839d.
Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease.
Zacharoff L, Tkac I, Song Q, Tang C, Bolan P, Mangia S
J Cereb Blood Flow Metab. 2011; 32(3):502-14.
PMID: 22044866
PMC: 3293115.
DOI: 10.1038/jcbfm.2011.157.